Orla Mining에 대한 매도 수량은 투자자에게 Orla Mining의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Orla Mining (AMEX:ORLA) 주식, 공매도 수량 보고

Orla Mining

Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Mexico, and the South Railroad and Lewis gold projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.

D-Wave Quantum Inc.

Equities

Mid Cap

News

Movers

Trading Ideas

HSAI

IONQ

ORLA

PTGX

QBTS

RGTI

SMTC

이 중형주들은 지난주에 가장 좋은 성과를 냈습니다. 당신의 포트폴리오에 있나요? 1. D-웨이브 퀀텀(NYSE:QBTS)의 주식은 회사가 4분기 수주가 1억 8,300만 달러로 전년 대비 502% 증가했다고 보고한 후 95.95% 상승했다.

D-웨이브 퀀텀과 아이온큐 등 지난주 급등한 중형주 8종목 (3월 10일-3월 14일)

Orla Mining Ltd

General

SOPH

SOPHiA GENETICS Reaches Over Two Million Genomic Profiles Analyzed

CNVS

Cineverse Announces A Strategic Partnership With The Trade Desk To Integrate Openpath With Cineverse's Ad Tech Platform, C360

Directors Join Board after Agreement with Icahn Enterprises
Caesars Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) ("Caesars") today announced the addition of two new independent directors to its Board of Directors. Jesse Lynn, General Counsel of Icahn Enterprises, and Ted Papapostolou, Chief Financial Officer of Icahn Enterprises, will join the Caesars Board effective immediately, subject to customary regulatory approvals.

Management

Caesars Entertainment Announces The Addition Of 2 New Independent Directors To Its Board Of Directors; Jesse Lynn, General Counsel, And Ted Papapostolou, CFO Of Icahn Enterprises, Will Join The Caesars Board Effective Immediately

Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) with a Overweight and maintains $7 price target.

Price Target

Reiteration

Analyst Ratings

MREO

Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target

Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Outperform and raises the price target from $42 to $44.

HRMY

Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $44

Mizuho analyst Robert Mosca maintains Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) with a Outperform and raises the price target from $248 to $254.

Mizuho Maintains Outperform on Cheniere Energy, Raises Price Target to $254

Joint offering to drive Enterprise AI adoption across manufacturing, financial services, and more
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc3.ai%2F&amp;esheet=54224897&amp;newsitemid=20250318262266&amp;lan=en-US&amp;anchor=C3+AI&amp;index=1&amp;md5=ca86a8eace7bb8a18a0039fd06b5c08a">C3 AI</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>), the leading Enterprise AI application software company, today announced a strategic alliance with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pwc.com%2Fus%2Fen.html&amp;esheet=54224897&amp;newsitemid=20250318262266&amp;lan=en-US&amp;anchor=PwC&amp;index=2&amp;md5=9966655333bee9ace24926cd8b6b9557">PwC</a>, a global leader in professional services, to deploy AI-powered business transformation at enterprise-scale across critical industries.

C3 AI And PwC Form Strategic Alliance To Drive Business Transformation Across Critical Industries

Molina Healthcare Wins Illinois Contract To Provide Dual Eligible Special Needs Plan; Terms Not Disclosed

WIIM

XTIA

XTI Aerospace shares are trading higher after the company announced up share repurchase program up to $5 million.

Cantor Fitzgerald analyst Jennifer Kim reiterates Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) from Overweight to Overweight.

BLTE

Cantor Fitzgerald Reiterates Overweight on Belite Bioto Overweight

Buybacks

XTI Aerospace Announces Up To $5M Share Repurchase Program

Contracts

TTEK

Tetra Tech Wins $416M In Civil Engineering Contracts With U.S. Army Corps Of Engineers Honolulu District

Cantor Fitzgerald analyst Kristen Kluska maintains Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Overweight and raises the price target from $99 to $132.

IRON

Cantor Fitzgerald Maintains Overweight on Disc Medicine, Raises Price Target to $132

N2OFF, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NITO#NASDAQ">NITO</a>), a clean tech firm focused on sustainable energy and agri-tech solutions, has entered into a <a href="https://www.benzinga.com/pressreleases/25/03/g44372663/n2off-signs-non-binding-loi-for-potential-380mw-battery-energy-storage-projects">non-binding letter of intent</a> (LOI) with SB Impact 4 Srl and Solterra Brand Services Italy Srl. 
The agreement is for the development of up to four additional utility-scale Battery Energy Storage System projects in Puglia, Italy. The new projects aim for a combined capacity of 380 MW. 
N2OFF is expanding its footprint in the energy storage sector with the development of large-scale battery storage projects in the Puglia region. 
The LOI between N2OFF, SB Impact 4 and Solterra outlines the possibility of acquiring and advancing these projects, some of which already have grid connections.
Also Read:<a href="https://www.benzinga.com/25/03/44372913/whats-going-on-with-nio-stock-today"> What&#8217;s Going On With NIO Stock Today?</a>
&#8220;This announcement marks yet another step forward in expanding our footprint in the energy storage sector,&#8221; said David Palah, CEO of N2OFF. &#8220;With these new projects, we aim to enhance grid stability and support the transition to a more resilient and sustainable energy infrastructure.&#8221;
These projects build on N2OFF's ongoing collaboration with Solterra Renewable Energy Ltd. in solar and energy storage ventures.
As part of the LOI, development milestones will include phased payments based on key stages like land reservation and permit acquisition. N2OFF's investment in Germany and Italy projects is projected to exceed €4.4 million, contributing to a combined capacity of more than 300 MW.
Price Action: NITO shares traded lower by 2.59% at $0.32 at last check Tuesday.
Read Next: <a href="https://www.benzinga.com/25/03/44374034/volkswagens-audi-to-slash-7500-jobs-by-2029-to-boost-competitiveness">Volkswagen&#8217;s Audi To Slash Up To 7,500 Jobs By 2029 To Boost Competitiveness</a>
Photo: Shutterstock

NITO

Clean Tech Company N2OFF Signs Deal For 380 MW Energy Storage Projects In Italy

Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $406.38, with a high estimate of $451.00 and a low estimate of $358.00. Observing a 4.37% increase, the current average has risen from the previous average price target of $389.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1742302869_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Cummins among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$375.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$451.00</td>
<td>$408.00</td>
</tr>
<tr>
<td>David Leiker</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$407.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$381.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$425.00</td>
<td>$424.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$430.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Michael Feniger</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$358.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$424.00</td>
<td>$369.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cummins. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cummins compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Cummins's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Cummins's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CMI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cummins analyst ratings.</a>
<h2>Delving into Cummins's Background</h2>
Cummins is the top manufacturer of diesel engines used in commercial trucks, off-highway machinery, and railroad locomotives, in addition to standby and prime power generators. The company also sells powertrain components, which include transmissions, turbochargers, aftertreatment systems, and fuel systems. Cummins is in the unique position of competing with its primary customers, heavy-duty truck manufacturers, who make and aggressively market their own engines. Despite robust competition across all its segments and increasing government regulation of carbon emissions, Cummins has maintained its leadership position in the industry.
<h3>Unraveling the Financial Story of Cummins</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Negative Revenue Trend: Examining Cummins's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -1.12% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 4.95%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Cummins's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.06%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Cummins's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.31%, the company showcases efficient use of assets and strong financial health.
Debt Management: Cummins's debt-to-equity ratio is below the industry average. With a ratio of 0.74, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Cummins: Insights From 8 Financial Analysts

During the last three months, 4 analysts shared their evaluations of Atmus Filtration Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATMU#NYSE">ATMU</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.0, a high estimate of $45.00, and a low estimate of $39.00. A 5.08% drop is evident in the current average compared to the previous average price target of $44.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1742302855_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Atmus Filtration Techs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Robert Mason</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Atmus Filtration Techs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Atmus Filtration Techs compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Atmus Filtration Techs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Atmus Filtration Techs's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ATMU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Atmus Filtration Techs analyst ratings.</a>
<h2>Unveiling the Story Behind Atmus Filtration Techs</h2>
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. It designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. It designs, manufactures, and sells filters, coolants, and chemical products. The company offers products for first-fit and aftermarket applications including air filters, fuel filters, fuel water separators, lube filters, hydraulic filters, coolants, fuel additives, and other filtration systems to original equipment manufacturers, dealers/distributors, and end-users.
<h3>Atmus Filtration Techs: Delving into Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Atmus Filtration Techs displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 1.75%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Atmus Filtration Techs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.86%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Atmus Filtration Techs's ROE stands out, surpassing industry averages. With an impressive ROE of 17.88%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Atmus Filtration Techs's ROA excels beyond industry benchmarks, reaching 3.33%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 2.78, Atmus Filtration Techs faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATMU

Analyst Expectations For Atmus Filtration Techs's Future

Dividends

QCOM

Qualcomm Increases Quarterly Dividend From $0.85 To $0.89/Share

During the last three months, 7 analysts shared their evaluations of AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for AVITA Medical, presenting an average target of $22.0, a high estimate of $25.00, and a low estimate of $14.00. This current average has decreased by 4.35% from the previous average price target of $23.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1742302846_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of AVITA Medical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brooks O'Neil</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ross Osborn</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to AVITA Medical. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of AVITA Medical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into AVITA Medical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RCEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AVITA Medical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind AVITA Medical</h2>
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
<h3>Key Indicators: AVITA Medical's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: AVITA Medical's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 29.67%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: AVITA Medical's net margin is impressive, surpassing industry averages. With a net margin of -62.96%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AVITA Medical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -138.57%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): AVITA Medical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -14.42%, the company may face hurdles in achieving optimal financial performance.
Debt Management: AVITA Medical's debt-to-equity ratio surpasses industry norms, standing at 10.22. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RCEL

What Analysts Are Saying About AVITA Medical Stock

Newell Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NYSE">NWL</a>) short percent of float has risen 4.37% since its last report. The company recently reported that it has 18.68 million shares sold short, which is 7.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Newell Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742302830_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Newell Brands has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Newell Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Newell Brands's peer group average for short interest as a percentage of float is 6.67%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Newell Brands?

In the latest quarter, 6 analysts provided ratings for Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $181.67, a high estimate of $205.00, and a low estimate of $155.00. Highlighting a 7.12% decrease, the current average has fallen from the previous average price target of $195.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1742302831_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Repligen's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Markowitz</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>In-Line</td>
<td>$155.00</td>
<td>-</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$170.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Repligen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Repligen compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Repligen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Repligen's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RGEN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Repligen analyst ratings.</a>
<h2>All You Need to Know About Repligen</h2>
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
<h3>Repligen's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Repligen showcased positive performance, achieving a revenue growth rate of 0.56% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Repligen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -20.21% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Repligen's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.7%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Repligen's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Repligen's debt-to-equity ratio is below the industry average. With a ratio of 0.35, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RGEN

Demystifying Repligen: Insights From 6 Analyst Reviews

Small Cap

Press Releases

Orla Mining Announces Strategic Expansion into Canada with Acquisition of the Musselwhite Gold Mine

The Week in Canadian Press Releases: 10 Stories You Need to See

Orla Mining Announces Appointment of New Chief Sustainability Officer

Orla Expands High-Grade Mineralization 800 Metres Beyond Current Resource in Extension Drilling at Camino Rojo, Mexico

Orla Mining Announces Filing of Special Meeting Materials and 43-101 Technical Report for Musselwhite Acquisition

Leading Independent Proxy Advisory Firms Recommend Orla's Shareholders Vote for the Proposed Acquisition of Musselwhite Mine from Newmont Corporation

Earnings

Orla Mining Achieves Record Annual Gold Production, Meets Improved 2024 Production Guidance, and Announces Preliminary 2025 Guidance

Orla Shareholders Approve Acquisition of Musselwhite Mine

Orla Mining Intersects High Grade Oxide Gold at South Carlin Complex and Advances Permitting for South Railroad Project in Nevada

Comments

Orla Mining

매도 수량

Orla Mining (AMEX:ORLA) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌